BIOCYTOGEN-B (02315) surged more than 3%, reaching HK$31.86 by the time of writing, with a trading volume of HK$12.99 million. The company announced that its partner IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision oncology therapeutics developer, has received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) to advance the first-in-class B7H3/PTK7 bispecific antibody-drug conjugate (ADC) project into Phase I clinical trials.

IDEAYA expects to begin patient enrollment in Q1 2026, initially evaluating B7H3 and PTK7 co-expressing solid tumors, including lung, colorectal, head and neck, and ovarian/gynecological cancers. Preclinical studies demonstrated that IDE034 monotherapy induced deep and durable tumor regression in multiple B7H3/PTK7-positive tumor models, exhibiting potent antitumor activity.

Additionally, IDEAYA plans to explore combination therapy strategies pairing IDE034 with its PARG inhibitor IDE161 to enhance efficacy durability. Further data supporting the mechanism of PARG and TOP1 ADC combination therapy will be presented at major medical conferences in H1 2026.

B7H3/PTK7 co-expression rates in lung, colorectal, and head and neck cancers are approximately 30%, 46%, and 27% respectively, highlighting broad clinical application potential.